Literature DB >> 14612191

Highly potent fluorescent analogues of the opioid peptide [Dmt1] DALDA.

Irena Berezowska1, Nga N Chung, Carole Lemieux, Bogumil Zelent, Hazel H Szeto, Peter W Schiller.   

Abstract

H-Dmt-D-Arg-Phe-Lys-NH2 (Dmt=2',6'-dimethyltyrosine) ([Dmt1] DALDA) is a highly potent and selective micro opioid peptide agonist capable of producing an antinociceptive effect after systemic administration. Fluorescent analogues of [Dmt1] DALDA containing either beta-dansyl-L-alpha,beta-diaminopropionic acid [Dap(dns)] or beta-anthraniloyl-L-alpha,beta-diaminopropionic acid [Dap(atn)] in place of Lys4 were synthesized. Both analogues retained subnanomolar mu opioid receptor binding affinity, very high mu opioid agonist activity in the guinea pig ileum assay and extraordinarily high antinociceptive activity in the mouse tail-flick test (intrathecal administration). The maxima of the fluorescence emission spectra recorded in Tris-HCl buffer (pH 6.6) indicated a completely aqueous environment of the fluorophore in both peptides. The high fluorescence quantum yield (phi=0.358) of the [Dap(atn)4] analogue was particularly remarkable. These fluorescent [Dmt1] DALDA analogues represent valuable pharmacological tools for various applications, including studies on the binding to receptors and other biopolymers, cellular uptake and intracellular distribution, and tissue distribution.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14612191     DOI: 10.1016/j.peptides.2003.07.004

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  7 in total

1.  Design, synthesis, and pharmacological characterization of fluorescent peptides for imaging human V1b vasopressin or oxytocin receptors.

Authors:  Maithé Corbani; Miguel Trueba; Stoytcho Stoev; Brigitte Murat; Julie Mion; Véra Boulay; Gilles Guillon; Maurice Manning
Journal:  J Med Chem       Date:  2011-03-23       Impact factor: 7.446

2.  6-N,N-dimethylamino-2,3-naphthalimide: a new environment-sensitive fluorescent probe in delta- and mu-selective opioid peptides.

Authors:  M Eugenio Vázquez; Juan B Blanco; Severo Salvadori; Claudio Trapella; Roberto Argazzi; Sharon D Bryant; Yunden Jinsmaa; Lawrence H Lazarus; Lucia Negri; Elisa Giannini; Roberta Lattanzi; Mariantonella Colucci; Gianfranco Balboni
Journal:  J Med Chem       Date:  2006-06-15       Impact factor: 7.446

Review 3.  Fluorescent approaches for understanding interactions of ligands with G protein coupled receptors.

Authors:  Rajashri Sridharan; Jeffrey Zuber; Sara M Connelly; Elizabeth Mathew; Mark E Dumont
Journal:  Biochim Biophys Acta       Date:  2013-09-18

Review 4.  Opioid peptide-derived analgesics.

Authors:  Peter W Schiller
Journal:  AAPS J       Date:  2005-10-14       Impact factor: 4.009

5.  Solid-phase synthetic strategy and bioevaluation of a labeled delta-opioid receptor ligand Dmt-Tic-Lys for in vivo imaging.

Authors:  Jatinder S Josan; David L Morse; Liping Xu; Maria Trissal; Brenda Baggett; Peg Davis; Josef Vagner; Robert J Gillies; Victor J Hruby
Journal:  Org Lett       Date:  2009-06-18       Impact factor: 6.005

6.  Synthesis and pharmacological evaluation of highly potent [Dmt1]DALDA analogs.

Authors:  P Anantha Reddy; Anita H Lewin; Peter W Schiller
Journal:  Adv Exp Med Biol       Date:  2009       Impact factor: 2.622

7.  Treatment of age-related visual impairment with a peptide acting on mitochondria.

Authors:  N M Alam; R M Douglas; G T Prusky
Journal:  Dis Model Mech       Date:  2022-02-21       Impact factor: 5.758

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.